Clinical Trial Detail

NCT ID NCT02273739
Title Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Agios Pharmaceuticals, Inc.
Indications

Advanced Solid Tumor

peripheral T-cell lymphoma

malignant glioma

Therapies

Enasidenib

Age Groups: adult

Additional content available in CKB BOOST